Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Summary not available.
Summary not available.
Bausch Health Companies Inc. (NYSE:BHC) partners with the Colorectal Cancer Alliance to enhance awareness and access to colorectal cancer screenings in Philadelphia. This initiative, launching in May, targets communities with significant health disparities. Salix Pharmaceuticals, a subsidiary, will provide its bowel preparation product to individuals requiring colonoscopies, essential for early cancer detection. With colorectal cancer's 90% survival rate if detected early, this partnership aims to address socioeconomic inequities that hinder screening access. Colorectal cancer remains a leading cause of cancer deaths in the U.S., with 106,970 estimated new colon cancer cases in 2023. Salix’s commitment signifies a proactive approach to public health and cancer prevention.
Bausch Health Companies (NYSE:BHC) will release its first-quarter financial results on May 4, 2023, at 8:00 a.m. U.S. EDT.
A conference call and live webcast will follow the results announcement, where the company will discuss its business updates. All relevant materials will be provided on the Investor Relations section of Bausch Health's website prior to the call.
Participants can register for the live Q&A session to receive a PIN before the call. The company, committed to enhancing global health, develops products primarily in fields like gastroenterology, neurology, and eye health.
Summary not available.
Bausch Health Companies Inc. (TSX:BHC)(NYSE:BHC) announced the retirement of board members Richard De Schutter and Dr. Argeris Karabelas, effective at the upcoming 2023 annual shareholder meeting. With their departure, the board size will reduce to 10 members. Chairperson John A. Paulson expressed gratitude for their contributions. The board's committee structure has been refreshed, details of which are available on the company's website. Bausch Health continues its mission to enhance lives through healthcare products across various sectors, including gastroenterology and eye health.
Bausch Health reported fourth-quarter revenues of $2.2 billion for 2022, flat compared to 2021 but up 4% organically. Full-year revenues were $8.1 billion, down 4% from 2021, but up 2% organically. The company reduced debt by $464 million in Q4 2022 and $3.2 billion since Bausch + Lomb's IPO. Operating loss for Q4 was $236 million due to a goodwill impairment charge. However, net loss for the year improved to $225 million from $948 million in 2021. Bausch Health forecasts 2023 revenues (excl. B+L) between $4.45 and $4.6 billion.
KBRA's fourth-quarter 2022 U.S. Bank Compendium offers insights into the U.S. banking sector, analyzing performance metrics and credit quality indicators for banks under KBRA's long-term ratings. The report highlights loan quality, loss absorption capacity, and key trends affecting bank performance amidst a low problem loan environment. It also details the top 10 banks with lowest cost deposit franchises and significant changes in financial ratios. Additionally, the Compendium features a quarterly ESG Bulletin, and a supplement with 158 debt issues from rated banks.
Bausch Health (NYSE/TSX:BHC) announced the opening of the 2023 Salix Gastrointestinal Health Scholars Program, offering scholarships of up to $10,000 to 10 students living with gastrointestinal (GI) diseases. This initiative, now in its fourth year, aims to support students in pursuing higher education. Applicants can apply until May 15, 2023, and must submit essays detailing their experiences with GI conditions. The program comprises various categories, including awards for undergraduate and graduate students, as well as scholarships for working and single parents. Recipients will be notified in summer 2023.
Bausch Health Companies Inc. (BHC) is set to announce its fourth-quarter and full-year financial results on February 23, 2023. The announcement will be followed by a conference call at 8:00 a.m. U.S. EST to discuss the results and provide a business update. Investors can access all related materials on the Investor Relations section of the Bausch Health website. A replay of the call will also be available there. Bausch Health operates globally, specializing in various pharmaceutical sectors, including gastroenterology, neurology, and eye health.